|
|
| home about us advertise with us downloads links privacy contact us site map copyright policy |
| ||
Integrated Approach To Irritable Bowel SyndromeOur understanding of the pathophysiology of the functional GI disorders, and in particular, irritable bowel syndrome (IBS), have evolved from an etiological concept of it being a disorder of abnormal motility to a more integrated understanding consistent with a biopsychosocial framework (1). It is a composite of several physiological components: dysmotility, visceral hypersensitivity, and abnormalities in brain-gut regulation (2). The IBS is defined as a functional gastrointestinal disorder of the lower bowel (and within the subgroup of functional bowel disorders) characterized by abdominal pain associated disturbed defecation (diarrhea or constipation), often with feelings of bloatedness and/or distension (2;3). Psychosocial disturbances are not a part of the definition and in fact, are not present in most persons with IBS. 1. Physical or psychological stimuli produce motility changes and altered bowel patterns and can lead to symptoms in healthyIrritable_Bowelbowel syndrome? Partly digested food normally leaves the stomach and passes into the small intestine and then into the large intestine. The large intestine is also called the large bowel or colon. In irritable bowel syndrome (IBS), the intestines squeeze too hard or not hard enough and cause food to move too fast or too slowly through your system. IBS is also called functional bowel syndrome, irritable colon, spastic bowel and spastic colon. It's not the same as inflammatory bowel diseases, like ulcerative colitis. The pain of IBS may go away when you pass gas or have a bowel movement. - Feeling like you still need to have a bowel movement after you've already had one - Feeling a strong urge to have a bowel movement irritable_bowelPhysical examination is typically, and frustratingly, normal for people with IBS, enlightening only in its ability to rule out other more serious illnesses such as colon cancer or inflammatory bowel disease. "It appears to be due to increased sensitivity in the bowel, coupled with abnormal bowel contractions, called peristalsis," says Sydney gastroenterologist Dr Katie Ellard. As distressing as it can be, IBS should not be confused with more serious bowel conditions, and does not cause them. either bowel cancer or coeliac disease, you shouldn't assume your symptoms are due to IBS. "Anyone developing symptoms over the age of 40 should see their doctor, so that other conditions with perhaps more serious consequences, like bowel cancer, can be ruled out," says Professor Bolin. Before making a diagnosis of IBS, the doctor will probably want to rule out other bowel conditions, including: Colon cancer. Bowel cancer is uncommon before the age of 40 but its incidence increases after1) I feel helpless because of my bowel problems. 2) I am embarrassed by the smell caused by my bowel problems. 4) I feel vulnerable to other illnesses because of my bowel problems. 5) I feel fat because of my bowel problems. 6) I feel like I am losing control of my life because of my bowel problems. 7) I feel my life is less enjoyable because of my bowel problems. 14) I feel like I irritate others because of my bowel problems. 16) I feel irritable because of my bowel problems. Proposed Mechanism: 5HT3 antagonist reduces bowel motility, increases fluid absorption in the bowel, and may have a central neural visceroanalgesic action Evidence: Five English-language RCT's all Level I untitledApproved for 2 AMA PRA category 1 credits ibs This highly interactive debate/discussion will involve discussion of the current controversies and newer management options in patients with irrita-ble bowel syndrome. Dr. Camilleri and Dr. Lembo are world renowned experts in the field of irrita-ble bowel syndrome and functional gastrointesti-nal disorders. The audience will be encouraged to submit/ask questions or present brief real life clin-ical cases during the debate. The participants will learn to integrate the newer diagnostic and treat-ment modalities for irritable bowel syndrome in their clinical practice. OBJECTIVES - Update on current algorithms in the workup of patients with irritable bowel syndrome, includ-ing the use of breath tests for identifying bac-terial overgrowth - Review the latest data on the role of probiotics in the treatment of irritable bowel syndrome - Update physicians on current and emerging treatment options for irritable bowel syndromeNVU-2390impactreport12.19The report, which was initiated and cospon-sored by the Society for Women's Health Research, examined the state of knowledge of -based biology and gender-based medicine and made recommendations for advancing an appropriate research agenda for this emerging field. Irritable Bowel Syndrome (IBS) is just one of the many disorders that takes an excessive toll on women. Among the latter, irritable bowel syndrome (IBS) is one of the least understood and most frustrating--for patients as well as for the medical community. About two thirds of enrollees were women.29 The survey focused on assessing the subjective rating of various sensory symptoms of IBS--abdominal pain, bloating, fullness, sensation of gas--for the previous 2 weeks; the degree to which patients were bothered by altered bowel habits was not assessed. I have to endure the additional abdominal pain and cramps from a laxative while shocking my system into a bowel movement and racing to the bathroom. The current gapsPlease call the HCM Department (800) 284-2273 if you have any questions regarding this form. Documentation must be present in the member's medical record with confirmation of Irritable Bowel Syndrome, chronic and/or idiopathic constipation. Tgaserod has FDA approval for short-term use. OSF HealthPlans will provide coverage for 12 weeks per 12- month interval. Does the patient have the diagnosis of constipation, bloating, and abdominal pain predominant from irritable bowel syndrome? _____ 7. Has the patient been informed that Zelnorm should be added to, and substituted for, her current medicine and non-medical treatments for irritable bowel syndrome? _____ 8. Requesting Zelnorm beyond FDA short-term usage requires consultation by a gastroenterology specialist. List date of visit and name of specialist: Completion of this form does not assure payment of requested services. FM-IBSBackground/aims: Irritable bowel syndrome is a functional bowel dis-order which is characterized by afferent visceral hypersensitivity. It is frequently observed in patients with fibromyalgia but the presence of fibromyalgia in patients with irritable bowel syndrome has not been well defined. The aim of this study was to assess the prevalence of fibromyal-gia and associated symptoms in patients with irritable bowel syndrome. Methods: Seventy-eight patients with irritable bowel syndrome diag-nosed according to Manning's criteria and 70 age and gender matched controls were included in the study. Conclusions: These results indicate that fibromyalgia and associated symptoms frequently coexist in irritable bowel syndrome. Irritable bowel syndrome (IBS) is a functional bowel dis-order associated with abdominal distension, abdominal pain and features of defecation disorders. Prevalence of fibromyalgia and associated symptoms in patients with irritable bowel syndrome (IBS) andIrritable Bowel Syndrome1Irritable bowel syndrome (IBS) is a biopsychosocial disorder, affecting the gastrointestinal (GI) tract, resulting in both upper and lower GI symptoms. The most common symptoms include abdominal pain, constipation or diarrhea, and bloating after eating. Stress or the ingestion of food often triggers symptoms. √ IBS represents about one half of all GI abnormalities. Apple and grape juice, bananas, nuts, and raisins may increase gas production. Dairy products should be consumed if tolerated, but may cause gas or bloating if lactose intolerance exists. Sorbitol and fructose are sweeteners that may disturb bowel function. - Sorbitol is an artificial sweetener used in dietetic food, and sugar free. Gums and fructose is a natural sugar in fruits, berries, and plants. Regular physical activity assists in bowel function and reduces stress.The orally delivered compound, MD-1100, is a potent superagonist of guanylate cyclase-C, a receptor found on the surface of intestinal cells. The Microbia drug discovery team designed MD-1100 to specifically target the intestine, the site of disease, without more general systemic exposure. The data were presented today in New Orleans at the Digestive Disease Week conference--the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. "We are encouraged by the potency and pharmacologic properties of MD-1100. Our data suggest that this compound is a very strong clinical candidate for constipation-predominant IBS," said Mark Currie, Ph.D., Vice President of Research and Development at Microbia. " Activation of a critical intestinal receptor by MD-1100 increases gastrointestinal fluid secretion and transit and decreases visceral pain--all issues that are crucial in treating IBS. ORLANDO, Fla., November 2, 2004--Microbia, Inc. today will present preclinical data demonstrating that MD-1100, its novel-mechanism therapeutic candidate for the treatment of constipation-predominant irritable bowel syndrome (c-IBS), effectively decreases gastrointestinal pain in multiple preclinical models. Gastrointestinal pain is a defining attribute of IBS and is the key symptom that motivates IBS sufferers to seek medical treatment. MD-1100, an orally delivered compound, is a potent superagonist of guanylate cyclase-C, a receptor found on the surface of intestinal cells. Designed by the Microbia drug discovery team, MD-1100 promotes gastrointestinal transit and secretion and specifically alleviates gastrointestinal pain. Microbia recently entered MD-1100 into Phase I clinical studies as a therapeutic candidate with the potential to treat irritable bowel syndrome. Microbia researchers will present findings today at the 69th American College of Gastroenterology 268Background/ aims: We planned to determine irritable bowel syndrome prevalence in our region with its distribution accord-ing to clinical characteristics of patients and the factors which are considered to be related with irritable bowel syndrome. Results: We found the irritable bowel syndrome prevalence in the city center of Sivas to be 19.1%. Distribution of irritable bowel syndrome (+) patients age groups showed no significant difference but irritable bowel syndrome was significantly more common in females. Irritable bowel syndrome prevalence was also significantly higher in persons not eating three regular meals per day. There was a signifi-cantly positive correlation between irritable bowel syndrome prevalence and psychological events, previous abdominal oper-ations and infections. A change in bowel habitus was observed in 41.8% of irritable bowel syndrome patients, and the most common change was constipation. 39.8% of the irritable bowel syndrome patients had applied toJune 05Many athletes experience bowel problems during trai nings and competition. This may just be a case of the ne rves on event day or it could be something more common such as Irritable Bowel Syndrome (IBS). What is Irritable Bowel Syndrome? Irritable Bowel Syndrome is characterised by changes in bowel habits such as diarrhoea, abdominal pain, dis tended abdomen, increased gas production, and other sympto ms including nausea, heartburn, backache and tiredness. It does affect about 15% of the population and is most commonly misdiagnosed by many. IBS affects people under the age of 35years and is found to be more common i n women than men. Stress is another factor that can contribute to IBS as well as genetics and environme ntal conditions. Other forms of treatment include meditation to help relieve stress, Aloe Vera juice and bowel medications. Fat is known to stimulate the bowel after eating and cause discomfort over the next day Avoid fizzy drinks and eat smaller meals morei-xv_IBS_2nd_ed_FMThis book, or any parts thereof, may not be reproduced in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without the written permission of the publisher. "Irritable Bowel Syndrome and the MindBodySpirit Connection is must reading for everyone who encounters this common condition--patients, their loved ones, and the health care providers who treat them. Drs. Salt and Neimark have writ-ten the definitive healing guide for the millions who suffer from functional bowel problems." Other books on functional symptoms and syndromes are under development. We don't have a simple answer--a pill or potion or quick fix--that will cure irritable bowel syndrome. He has spent over 24 years caring for patients with digestive and liver diseases and has a special interest in irritable bowel syndrome, as well as other functional disorders. Dr. Salt is the author of the first edition and coauthor of the revisedFactsheet General . webIrritable Bowel Syndrome or IBS is the name doctors have given to a collection of otherwise unexplained symptoms relating to a dis-turbance of the large bowel. For that reason, IBS is often called `a functional disorder' of the bowel; in other words, an illness associ-ated with a disturbance of bowel function without any change in structure or obvious cause. A similar range of symptoms is reported by patients with other med-ically unexplained illnesses, such as Chronic Fatigue Syndrome, Fibromyalgia, Food Intolerance and Functional Dyspepsia. IBS should always be diagnosed by a qualified medical practitioner, since the symptoms of IBS can resemble those of other bowel dis-eases. -fever - an abrupt and persistent unexplained change in bowel habit in somebody above the age of 40 The quick answer to that is `we all do', though some people get it more severely than others. Our bowels are not always as regular as clockwork and bloating and abdominal pain are very commonWorld of Drug Information1. Recognize the most common symptoms associated with irritable bowel syndrome. 4. Discuss drug therapy for constipation-predominant irritable bowel syndrome currently in clinical trials. Irritable bowel syndrome therapy is directed at the patients' overall well-being and not just at symptoms.8 Patients need a trusting relationship with their care providers who provide patients with the tools to understand their disease.8 Emphasis is placed on following an appropriate diet and making certain lifestyle changes.8 If necessary, drug therapy can be used In irritable bowel syndrome these receptors may be hypersensitive. Irritable bowel syndrome is more common in women, so tegaserod studies have involved mostly women.1 Of the three trials conducted and submitted for approval of tegaserod, only the study by Muller-Lissner and colleagues1 has been published. Tegaserod is currently the only drug approved in the U.S. specifically forIBS Reviewgastroenterologists have been uncomfortable diagnosing irritable bowel syndrome (IBS), in part because we have had few treatments for IBS we could feel confident about. EPIDEMIOLOGY: IBS IS COMMON Irritable bowel syndrome is a highly prevalent disorder, affecting about 10% to 15% of North Americans. Weight loss, anemia, occult blood in the stool History of travel to locations with endemic parasitic diseases Nighttime symptoms New onset after age 50 Family history of colon cancer, inflammatory bowel disease, or celiac disease Arthritis or skin findings on physical examination Signs or symptoms of malabsorption Somatoform disorders can be more challenging.11 Notably, psychological disturbance has been shown to influence the patient's severity of bowel symptoms and level of disability.12 As a result, asking patients about key symptoms of mood disorders, anxiety, and depression can be helpful, since addressing such symp-toms will often improve their bowel symptoms.7 However,Lotronex (alosteron) Please call the HCM Department (800) 284-2273 or the Rockford Region (800) 375-5716 if you have any questions regarding this form. Date: Patient Name: DOB: ID No.: Doctor: Person Completing Report: Contact Phone No.: Documentation must be present in the member's medical record with confirmation of Irritable Bowel Syndrome. 2. Does the patient have the diagnosis of diarrhea predominant irritable bowel syndrome? _____ 7. Has the patient been informed that Lotronex should be added to, and substituted for, her current medicine and non-medical treatments for irritable bowel syndrome? _____ 1 | 2 | 3
| 4 | 5 | 6
| 7 | 8 | 9
| 10 | 11 | 12
| 14 | 15 | | ||
